BridgeBio Introduces Company at 'BIO USA'... "Unveiling New Diagnostic Business"

Bridge Biotherapeutics announced on the 30th that it has been selected as a "presenting company" to introduce its latest business progress at the "2023 BIO International Convention (BIO USA)" to be held in the United States on the 5th of next month.

Bridge Biotherapeutics logo. [Photo by Bridge Biotherapeutics]

BIO USA is the world's largest partnering event where over 14,000 pharmaceutical and biotech industry experts from more than 60 countries gather to share innovative new drug research and development achievements and explore new collaboration opportunities. This year's event will be held for four days from the 5th to the 8th of next month in Boston, USA.

Bridge Biotherapeutics will conduct a corporate presentation for industry stakeholders and potential partners on the afternoon of the 6th (local time). Pavel Prinsev, Director of Business Development, will introduce the company's business vision centered on innovative new drugs, as well as the latest research and development status and prospects in the fields of lung cancer and pulmonary fibrosis. In particular, the company will showcase its new business, which has been actively launched following the recent acquisition of diagnostic technology.

The company plans to meet with existing and new negotiation partners related to its lung cancer pipeline to deeply discuss the possibility of technology transfer. In addition, it stated that it will devote itself to exploring various forms of business development opportunities such as joint development and introduction of new projects.

Bridge Biotherapeutics recently announced a strategy to establish a virtuous business cycle by strengthening clinical development capabilities, internalizing key clinical functions, and acquiring Ellipse Diagnostics, which holds proprietary patented technology, to self-finance the funds necessary for new drug clinical development.

Lee Jung-kyu, CEO of Bridge Biotherapeutics, said, "We are very honored to provide meaningful updates on the company's latest trends and challenges, including new businesses, at the world's largest pharmaceutical and biotech partnering event." He added, "We will actively utilize face-to-face partnering meetings and corporate presentation sessions to promote the company's competitiveness in the global market and do our best to promptly complete additional negotiation procedures for technology transfer to achieve results."

Meanwhile, Boston, USA, where this event is held, is one of the world's largest bio clusters. Bridge Biotherapeutics established its Boston-based subsidiary, Boston Discovery Center (BDC), in 2020.